Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Euro Pacific Asset Management LLC Reduces Position in Novartis AG $NVS
04:31am, Tuesday, 31'st Mar 2026
Euro Pacific Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE: NVS) by 54.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Co
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
01:15am, Sunday, 29'th Mar 2026
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statisti
Novartis Bolsters Immunology Pipeline With Excellergy Deal
03:55pm, Friday, 27'th Mar 2026
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy
10:45am, Friday, 27'th Mar 2026
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for allergic diseases. Under the agreement, Novartis
International ETFs: EEM and IEFA Offer Distinct Global ETF Choices
10:08am, Friday, 27'th Mar 2026
Expense, risk, and sector focus set these two ETFs apart-see which aligns better with your global investing strategy.
Novartis Expands Pipeline With $2 Billion Biotech Deal
09:29am, Friday, 27'th Mar 2026
Novartis (NVS, Financials) agreed to buy Excellergy, a biotech company located in the U.S., for up to $2 billion. This is part of a string of recent investments
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
07:43am, Friday, 27'th Mar 2026
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy
06:24am, Friday, 27'th Mar 2026
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for...
Novartis to Buy Biotech Excellergy for Up to $2 Billion
02:33am, Friday, 27'th Mar 2026
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
02:28am, Friday, 27'th Mar 2026
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transacti
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
02:00am, Friday, 27'th Mar 2026
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism d
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
04:41pm, Monday, 23'rd Mar 2026
Novartis AG faces significant patent expiries but is aggressively acquiring pipeline assets, including a $2bn deal for Pikavation and a $12bn buyout of Avidity. NVS projects >5% annual revenue growth
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
02:15am, Monday, 23'rd Mar 2026
Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year's American Academy of Dermatology (AAD) Annual Meeting.
Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
08:58am, Sunday, 22'nd Mar 2026
Novartis maintains a 'Strong Buy' rating, driven by resilient 2025 sales growth of 8% to $54.53 billion and robust product performance. NVS is actively strengthening its pipeline with strategic acquis
